Archived Investigations
Boston Scientific Corporation (NYSE: BSX)
Boston Scientific and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 4, 2026, pre-market, the Company announced its fourth quarter and full year 2025 results, disclosing disappointing U.S. Electrophysiology (“EP”) sales, and guidance for fiscal 2026 that fell well below expectations due to a combination of slower than expected market growth alongside increased competition, despite management’s previous claims of a “growing” EP business and assertions they “have a very good understanding of what competition we will face and in what time frame.”
On this news, the price of Boston Scientific’s shares fell from a closing market price of $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026, a decline of about 17.6% in the span of just a single day.
The case is John Rudolph Troike v. Boston Scientific Corporation, et al., Case No. 26-cv-40075.